Evidence map›Paper›PMID 41928902›Full record

ArticleTherapeutic advances in musculoskeletal disease2026

Definition of the terms used to describe psoriatic disease datasets: a HIPPOCRATES initiative.

Oliver FitzGerald, Catherine Smith, Christine Huppertz, Martin Brom, Dario Bruno, Philip S Helliwell, Marleen van de Sande, Maarten de Wit, Lars Werner, Vassilios Ioannidis and 5 more

Abstract read
In one paragraph

Article in Therapeutic advances in musculoskeletal disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Oliver FitzGeraldSchool of Medicine, Conway Institute for Biomolecular Research, University College Dublin, Belfield, Dublin 4, Ireland.ORCID https://orcid.org/0000-0002-6607-6070
Catherine SmithSt John's Institute of Dermatology, King's College London, London, UK.ORCID https://orcid.org/0000-0001-9918-1144
Christine HuppertzTranslational Research, Novartis Biomedical Research, Basel, Switzerland.ORCID https://orcid.org/0000-0002-0758-2395
Martin BromTranslational Medicine, Novartis Biomedical Research, Basel, Switzerland.
Dario BrunoRheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.ORCID https://orcid.org/0000-0002-6647-9208
Philip S HelliwellLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Marleen van de SandeDepartment of Rheumatology and Clinical Immunology, Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0003-0966-878X
Maarten de WitHIPPOCRATES Patient Research Partner, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-8428-6354
Lars WernerHIPPOCRATES Patient Research Partner, Copenhagen, Denmark.
Vassilios IoannidisVital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
Diana MarekVital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
Mark IbbersonVital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
Stephen R PenningtonConway Institute for Biomolecular Research, School of Medicine, University College Dublin, Dublin, Ireland.ORCID https://orcid.org/0000-0001-7529-1015
Michaela KoehmTranslational Rheumatology, Immunology - Inflammation Medicine, University Medicine Goethe-University, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP and Fraunhofer Cluster of Excellence Immune Mediated Diseases, Frankfurt, Germany.
Frank BehrensTranslational Rheumatology, Immunology - Inflammation Medicine, University Medicine Goethe-University, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP and Fraunhofer Cluster of Excellence Immune Mediated Diseases, Frankfurt, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriatic arthritis (PsA) is a complex, multisystem disease with no diagnostic criteria and discordant approaches to assessing disease activity and response to treatment. PsA is part of the Psoriatic Disease spectrum, encompassing cutaneous psoriasis and nail changes, PsA and in some cases, uveitis and inflammatory bowel disease. The HIPPOCRATES consortium is addressing unmet needs in PsA and has now established a harmonised data platform, the Secure HIPPOCRATES Data Management Platform (SHDMP), which will be transformative in providing researchers with the ability to interrogate at scale psoriatic disease datasets. The SHDMP datasets are diverse and include people with psoriasis being followed for the development of PsA, as well as cross-sectional, observational and randomised control trial data on people with PsA. To better understand and describe the nature of the SHDMP datasets, the HIPPOCRATES consortium has now defined and agreed on the terms that will be applied to each dataset. In this short report, the process adopted to obtain consensus on the dataset definition and the final set of terms agreed upon is described and discussed. The agreement on the terms to be used will greatly enhance a researcher's ability to select the appropriate SHDMP datasets to study.

Indexed as

dataset termspsoriasispsoriatic arthritis

Identifiers

PMID41928902
PMCPMC13039602

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.